News Headlines Article

Kaiser Permanente Charges FDA Drug Approval Process Excludes Healthcare Providers
Health Leaders Media - Joe Cantlupe

When the U.S. Food and Drug Administration evaluates new drug products for possible approval, the review process includes a risk-safety analysis known as Risk Evaluation and Mitigation Strategies (REMS). Kaiser Permanente, the nation’s largest publicly integrated healthcare delivery system, says the FDA has improperly excluded health insurers and others out of the REMS process, which was designed to improve drug safety.

Commands